Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review
Breast cancer (BC) occupies a leading position among all malignant neoplasms in women worldwide and is the 4th deadliest. Most cases are diagnosed in stages I–III. Among the molecular biological variants, luminal HER2 negative (HER2-) prevails, accounting for 70–75%. Currently, therapies combining s...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2023-12-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/627192/142916 |